Estadísticas

 array:23 [
  "pii" => "S0025775314701022"
  "issn" => "00257753"
  "doi" => "10.1016/S0025-7753(14)70102-2"
  "estado" => "S300"
  "fechaPublicacion" => "2014-09-01"
  "aid" => "70102"
  "copyright" => "Elsevier España, S.L.U.. Todos los derechos reservados"
  "copyrightAnyo" => "2014"
  "documento" => "article"
  "crossmark" => 0
  "subdocumento" => "fla"
  "cita" => "Med Clin. 2014;143 Supl 2:8-11"
  "abierto" => array:3 [
    "ES" => false
    "ES2" => false
    "LATM" => false
  ]
  "gratuito" => false
  "lecturas" => array:2 [
    "total" => 505
    "formatos" => array:3 [
      "EPUB" => 8
      "HTML" => 290
      "PDF" => 207
    ]
  ]
  "itemSiguiente" => array:18 [
    "pii" => "S0025775314701034"
    "issn" => "00257753"
    "doi" => "10.1016/S0025-7753(14)70103-4"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "aid" => "70103"
    "copyright" => "Elsevier España, S.L.U."
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2014;143 Supl 2:12-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 1482
      "formatos" => array:3 [
        "EPUB" => 2
        "HTML" => 506
        "PDF" => 974
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Características y tipos de agonistas del receptor de GLP-1. Una oportunidad más para la individualización terapéutica"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "12"
          "paginaFinal" => "17"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Esteban Jódar"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Esteban"
              "apellidos" => "Jódar"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701034?idApp=UINPBA00004N"
    "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701034/v1_201410180334/es/main.assets"
  ]
  "itemAnterior" => array:18 [
    "pii" => "S0025775314701010"
    "issn" => "00257753"
    "doi" => "10.1016/S0025-7753(14)70101-0"
    "estado" => "S300"
    "fechaPublicacion" => "2014-09-01"
    "aid" => "70101"
    "copyright" => "Elsevier España, S.L.U."
    "documento" => "article"
    "crossmark" => 0
    "subdocumento" => "fla"
    "cita" => "Med Clin. 2014;143 Supl 2:2-7"
    "abierto" => array:3 [
      "ES" => false
      "ES2" => false
      "LATM" => false
    ]
    "gratuito" => false
    "lecturas" => array:2 [
      "total" => 767
      "formatos" => array:3 [
        "EPUB" => 1
        "HTML" => 463
        "PDF" => 303
      ]
    ]
    "es" => array:10 [
      "idiomaDefecto" => true
      "titulo" => "Fisiología del GLP-1 y su papel en la fisiopatología de la diabetes mellitus tipo 2"
      "tienePdf" => "es"
      "tieneTextoCompleto" => 0
      "tieneResumen" => array:2 [
        0 => "es"
        1 => "en"
      ]
      "paginas" => array:1 [
        0 => array:2 [
          "paginaInicial" => "2"
          "paginaFinal" => "7"
        ]
      ]
      "titulosAlternativos" => array:1 [
        "en" => array:1 [
          "titulo" => "The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus"
        ]
      ]
      "contieneResumen" => array:2 [
        "es" => true
        "en" => true
      ]
      "contienePdf" => array:1 [
        "es" => true
      ]
      "autores" => array:1 [
        0 => array:2 [
          "autoresLista" => "Francisco Javier Escalada"
          "autores" => array:1 [
            0 => array:2 [
              "nombre" => "Francisco Javier"
              "apellidos" => "Escalada"
            ]
          ]
        ]
      ]
    ]
    "idiomaDefecto" => "es"
    "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701010?idApp=UINPBA00004N"
    "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701010/v1_201410180334/es/main.assets"
  ]
  "es" => array:11 [
    "idiomaDefecto" => true
    "titulo" => "Modulación del efecto incretina en el tratamiento de la diabetes"
    "tieneTextoCompleto" => 0
    "paginas" => array:1 [
      0 => array:2 [
        "paginaInicial" => "8"
        "paginaFinal" => "11"
      ]
    ]
    "autores" => array:1 [
      0 => array:3 [
        "autoresLista" => "Josep Vidal"
        "autores" => array:1 [
          0 => array:3 [
            "nombre" => "Josep"
            "apellidos" => "Vidal"
            "email" => array:1 [
              0 => "jovidal@clinic.ub.es"
            ]
          ]
        ]
        "afiliaciones" => array:1 [
          0 => array:2 [
            "entidad" => "Servicio de Endocrinología y Nutrición, Hospital Clínic, Barcelona, España"
            "identificador" => "aff0005"
          ]
        ]
      ]
    ]
    "titulosAlternativos" => array:1 [
      "en" => array:1 [
        "titulo" => "Modulation of the incretin effect in the treatment of diabetes"
      ]
    ]
    "pdfFichero" => "main.pdf"
    "tienePdf" => true
    "PalabrasClave" => array:2 [
      "es" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Palabras clave"
          "identificador" => "xpalclavsec355644"
          "palabras" => array:9 [
            0 => "Análogo GLP-1"
            1 => "Análogo receptor GLP-1"
            2 => "Diabetes"
            3 => "GIP"
            4 => "GLP-1"
            5 => "Glucagón"
            6 => "Incretina"
            7 => "Inhibidor DPP-4"
            8 => "Vaciamiento gástrico"
          ]
        ]
      ]
      "en" => array:1 [
        0 => array:4 [
          "clase" => "keyword"
          "titulo" => "Keywords"
          "identificador" => "xpalclavsec355643"
          "palabras" => array:9 [
            0 => "GLP-1 analog"
            1 => "GLP-1 analog receptor"
            2 => "Diabetes"
            3 => "GIP"
            4 => "GLP-1"
            5 => "Glucagon"
            6 => "Incretin"
            7 => "DPP-4 inhibitor"
            8 => "Gastric emptying"
          ]
        ]
      ]
    ]
    "tieneResumen" => true
    "resumen" => array:2 [
      "es" => array:2 [
        "titulo" => "Resumen"
        "resumen" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">La modulaci&#243;n del efecto incretina ha abierto una nueva estrategia en el tratamiento de la diabetes mellitus tipo 2 &#40;DM2&#41;&#46; La potenciaci&#243;n de este mecanismo fisiol&#243;gico se ha conseguido hasta la fecha por dos v&#237;as&#46; De una parte&#44; la inhibici&#243;n farmacol&#243;gica de la enzima que degrada fisiol&#243;gicamente a p&#233;ptido similar al glucag&#243;n-1 &#40;GLP-1&#41;&#44; la dipeptidil peptidasa-4 &#40;DPP-4&#41;&#46; Por otra&#44; el desarrollo de mol&#233;culas agonistas del receptor de GLP-1 &#40;arGLP-1&#41; resistentes a la acci&#243;n de la DPP-4&#46; Distintos ensayos cl&#237;nicos han demostrado la mayor eficacia cl&#237;nica de los arGLP-1&#44; lo cual parecer&#237;a ligado al alcance de mayores niveles circulantes de GLP-1&#46; En contrapartida&#44; esta parece ser la base tambi&#233;n de la mayor tasa de efectos adversos asociados al tratamiento con arGLP-1 en comparaci&#243;n con la inhibici&#243;n de DPP-4&#46; La valoraci&#243;n de estas y otras caracter&#237;sticas diferenciadoras de ambas familias de f&#225;rmacos deber&#225; marcar nuestra elecci&#243;n en el tratamiento personalizado de la hiperglucemia en el paciente con DM2&#46;</p>"
      ]
      "en" => array:2 [
        "titulo" => "Abstract"
        "resumen" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Modulation of the incretin effect has opened up a new strategy in the treatment of diabetes mellitus type 2 &#40;DM2&#41;&#46; To date&#44; this physiological mechanism has been boosted in two ways&#58; firstly&#44; by pharmacological inhibition of the enzyme that physiologically degrades glucagon-like peptide-1 &#40;GLP-1&#41; receptor agonists&#44; dipeptidyl peptidase-4 &#40;DPP4&#41;&#59; secondly&#44; through the development of GLP-1 agonists &#40;GLP-1a&#41; that are resistant to the action of DPP-4&#46; Several clinical trials have shown the clinical superiority of GLPa&#44; which seems to be linked to higher circulating levels of GLP-1&#46; On the other hand&#44; this higher efficacy also seems to be associated with the higher rate of adverse effects associated with aGLP-1 therapy compared with DPP-4 inhibition&#46; These and other differentiating characteristics of the two drug families will determine the choice of drug therapy in the personalized treatment of hyperglycemia in patients with DM2&#46;</p>"
      ]
    ]
  ]
  "idiomaDefecto" => "es"
  "url" => "/00257753/00000143000000S2/v1_201410180334/S0025775314701022/v1_201410180334/es/main.assets"
  "Apartado" => null
  "PDF" => "https://static.elsevier.es/multimedia/00257753/00000143000000S2/v1_201410180334/S0025775314701022/v1_201410180334/es/main.pdf?idApp=UINPBA00004N&text.app=https://www.elsevier.es/"
  "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0025775314701022?idApp=UINPBA00004N"
]